Benicar (Olmesartan Medoxomil) Patent Expiration, LOE Window & CMS Spending
Benicar (Olmesartan Medoxomil) by Cosette: Off-Patent Genericized (AB Competition), 18 AB generics, $14.3M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Cosette |
| FDA Application & Pathway | N021286 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 18 |
| 2024 CMS Total Public Spend | $14.3M |
| 2024 Medicare Part D Spend | $14.0M |
| 2024 Medicaid Spend | $321K |
| Reported Wholesale Price Change (CA SB 17) | 6 WAC filings (max 32.9% 2-yr change) |